Kate Moodie

Alpelisib Monotherapy for PI3K-Altered Pretreated Advanced Breast Cancer A Phase II Study

Peter Savas, Louisa L Lo, Stephen J Luen, Elizabeth F Blackley, Jason Callahan, Kate Moodie, Courtney T van Geelen, Yi-An Ko, Chen-Fang Weng, Lironne Wein, Maria Joao Silva, Andjelija Zivanovic Bujak, Miriam M Yeung, Sarah Ftouni, Rodney J Hicks, Prudence A Francis, Chee Khoon Lee, Sarah-Jane Dawson, Sherene Loi

Journal article  |  2022  |  CANCER DISCOVERY

UNLABELLED: There is limited knowledge on the benefit of the α-subunit-specific PI3K inhibitor alpelisib in later lines of therapy..

Abstract P1-18-14: Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: A phase II study

Peter Savas, Louisa Lisa Lo, Stephen James Luen, Elizabeth Fay Blackley, Courtney Templeton van Geelen, Yi-An Ko, Kate Moodie, Jason William Callahan, Chen-Fang Weng, Andjelija Zivanovic Bujak, Miriam Manning Yeung, Sarah Ftouni, Prudence Anne Francis, Sarah-Jane Dawson, Sherene Loi

Conference Proceedings  |  2022  |  Cancer Research

Abstract Background: The PI3Kα subunit specific inhibitor alpelisib in combination with fulvestrant is approved in ..

The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations

Tamara Hettipathirana, Courtney Macdonald, Jing Xie, Kate Moodie, Chris Michael, Kelly-Anne Phillips

Journal article  |  2021  |  MEDICAL JOURNAL OF AUSTRALIA

OBJECTIVE: To assess the sensitivity and specificity of clinical breast examination for detecting breast cancer in asymptomatic wo..